Discussion
T stage, malignancy, Prostate Cancer, noncutaneous malignancy, deaths, mCRPC
PROSTATE CANCER, PROSTATE CANCER, LYMPH NODE METASTASES, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
PC is the most common noncutaneous malignancy in men in the United States and its incidence is only increasing, with 268,490 new patients expected in the United States by 2022 and an expected 34,500 deaths from PC in the United StatesWith PC as the most common malignancy in developed countries, most patients have an age of diagnosis of over 65 years of agePrevious literature has reported that the risk of PC varies between ethnic groups, with increased risk in African men and reducedOur nomogram shows that TNM stage is also an independent risk factor for CSS in elderly nonsurgical PC patients, and patients with distant as well as lymph node metastases have worse outcomes than nonmetastases and higher T stage, which is consistent with previous studiesRT provides a treatment for localized PC without major surgery and is the preferred treatment in many menSince the 1940s, androgen ablation therapy has been the mainstay of treatment for prostate cancer, but drug resistance has developed over time. Thus, between the 1950s and 1970s, a number of small trials using alkylating agents were conducted, which was the original chemotherapy for prostate cancer. However, the initial chemotherapy results were not significant. In 1972, the National Prostate Cancer Project (NPCP) began a series of randomized single-agent and phase III combination studies called "hormone resistance" but later created "castration-resistant" PCa patients. Chemotherapy is not the primary treatment for prostate cancer, but docetaxel has improved overall survival in metastatic castration-resistant prostate cancer (mCRPC); however, combination chemotherapy or any drug added to docetaxel has failed to produce more benefitAlthough the nomogram established based on the SEER database has good accuracy, there are some potential limitations simultaneously, including the lack of some important clinicopathological variables, such as smoking, alcohol consumption, and haemoglobin. In addition, AS and ADT are also the main nonsurgical treatments for nonsurgical PC patients. Meanwhile, ADT, as one of the nonsurgical treatment options for patients with prostate cancer, is usually used for high-risk local or systemic advanced PC that is not suitable for radical surgery. Although ADT was explored in Beebe-Dimmer and Muralidhar et al. in the SEER-based study